[go: up one dir, main page]

AR095326A1 - Heterociclos tricíclicos como inhibidores de la proteína bet - Google Patents

Heterociclos tricíclicos como inhibidores de la proteína bet

Info

Publication number
AR095326A1
AR095326A1 ARP140101029A ARP140101029A AR095326A1 AR 095326 A1 AR095326 A1 AR 095326A1 AR P140101029 A ARP140101029 A AR P140101029A AR P140101029 A ARP140101029 A AR P140101029A AR 095326 A1 AR095326 A1 AR 095326A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
cycloalkyl
halo
independently selected
Prior art date
Application number
ARP140101029A
Other languages
English (en)
Inventor
D Rodgers James
P Combs Andrew
B Sparks Richard
P Jr Maduskuie Tomas
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR095326A1 publication Critical patent/AR095326A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque: ⁻ ⁻ ⁻ ⁻ ⁻ representa un enlace sencillo o un enlace doble; L es CR⁹R⁹ᵃ, O, S, SO, o SO₂; Cy¹ es seleccionado de fenilo o un grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, en donde el fenilo o heteroarilo de 5 - 6 miembros Cy¹ es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹¹; R¹ y R² son seleccionados independientemente de H, halo, CN, OH, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, ORᵃ¹, SRᵃ¹, C(=O)Rᵇ¹, C(=O)NRᶜ¹Rᵈ¹, C(=O)ORᵃ¹, OC(=O)Rᵇ¹, OC(=O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)Rᵇ¹, NRᶜ¹C(=O)NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)ORᵃ¹, S(=O)Rᵇ¹, S(=O)NRᶜ¹Rᵈ¹, S(=O)₂Rᵇ¹, NRᶜ¹S(=O)₂Rᵇ¹ y S(=O)₂NRᶜ¹Rᵈ¹, en donde el alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ de R¹ y R² son opcionalmente sustituidos con 1, 2, ó 3 grupos seleccionados independientemente de halo, CN, OH, ORᵃ¹, SRᵃ¹, C(=O)Rᵇ¹, C(=O)NRᶜ¹Rᵈ¹, C(=O)ORᵃ¹, OC(=O)Rᵇ¹, OC(=O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)Rᵇ¹, NRᶜ¹C(=O)NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)ORᵃ¹, S(=O)Rᵇ¹, S(=O)NRᶜ¹Rᵈ¹, S(=O)₂Rᵇ¹, NRᶜ¹S(=O)₂Rᵇ¹ y S(=O)₂NRᶜ¹Rᵈ¹; siempre que ni R¹ ni R² sean Cl, Br, I, CN, u OH cuando L es O ó S; alternativamente, R¹ y R² junto con el átomo de carbono al cual se unen se combinan para formar un grupo cicloalquilo C₃₋₇, en donde el grupo cicloalquilo es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R²⁰; Cy³ es seleccionado de fenilo, cicloalquilo C₃₋₇, un grupo heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 10 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 10 miembros, y heterocicloalquilo de 4 - 10 miembros de Cy³ es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹³, en donde un átomo de nitrógeno formador del anillo del grupo heteroarilo de 5 - 10 miembros o un átomo de nitrógeno formador del anillo del grupo heterocicloalquilo de 4 - 10 miembros es opcionalmente oxidado; R⁴ es H, C(=O)NR¹⁴ᵃR¹⁴ᵇ, C(=O)R¹⁴ᵃ, C(=O)OR¹⁴ᵃ, o alquilo C₁₋₆ opcionalmente sustituido por 1, 2, ó 3 sustituyentes seleccionados independientemente de halo, NR¹⁴ᵃR¹⁴ᵇ, OR¹⁴ᵃ, SR¹⁴ᵃ, CN, C(=O)R¹⁴ᵃ, C(=O)NR¹⁴ᵃR¹⁴ᵇ, C(=O)OR¹⁴ᵃ, OC(=O)R¹⁴ᵇ, OC(=O)NR¹⁴ᵃR¹⁴ᵇ, NR¹⁴ᵃC(=O)R¹⁴ᵇ, NR¹⁴ᵃC(=O)NR¹⁴ᵃR¹⁴ᵇ, NR¹⁴ᵃC(=O)OR¹⁴ᵇ, S(=O)R¹⁴ᵃ, S(=O)NR¹⁴ᵃR¹⁴ᵇ, S(=O)R¹⁴ᵃ, NR¹⁴ᵃS(=O)₂R¹⁴ᵇ, y S(=O)₂NR¹⁴ᵃR¹⁴ᵇ; R⁵ es seleccionado de =O y =S cuando C⁻ ⁻ ⁻ ⁻N es un enlace sencillo, alternativamente, cuando C⁻ ⁻ ⁻ ⁻N es un enlace doble entonces R⁵ es seleccionado de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, NR¹⁵ᵃR¹⁵ᵇ, -C(=O)NR¹⁵ᵃR¹⁵ᵇ, -C(=O)OR¹⁵ᵃ, fenilo, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 10 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el alquilo, fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 6 miembros, y heterocicloalquilo de 4 - 10 miembros de R⁵ es opcionalmente sustituido por 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹⁵; R⁶ es seleccionado de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆, en donde el alquilo, alquenilo, y alquinilo de R⁶ son cada uno opcionalmente sustituidos por 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹⁶; alternativamente, R⁶ es seleccionado de arilo C₆₋₁₀, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 7 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el arilo C₆₋₁₀, cicloalquilo C₃₋₇, heteroarilo de 5 - 10 miembros, y heterocicloalquilo de 4 - 7 miembros de R⁶ son cada uno opcionalmente sustituidos por 1, 2, 3, ó 4 grupos seleccionados independientemente de R²⁰; R⁷ es seleccionado de H, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, C(=O)NRᶜRᵈ, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, fenilo, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 7 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el alquilo, alquenilo, alquinilo, fenilo, cicloalquilo, grupo heteroarilo de 5 - 6 miembros, y un grupo heterocicloalquilo de 4 - 7 miembros de R⁷ son opcionalmente sustituidos con 1, 2, ó 3 grupos seleccionados independientemente de R¹⁷; R⁸ es seleccionado de H, alquilo C₁₋₃, alquenilo C₂₋₃, alquinilo C₂₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ, en donde el alquilo C₁₋₃ de R⁸ es opcionalmente sustituido con 1, 2, ó 3 grupos seleccionados independientemente de R¹⁸; R⁹ y R⁹ᵃ son seleccionados independientemente de H, alquilo C₁₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ; R¹¹ independientemente en cada caso es seleccionado de H, alquilo C₁₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ, en donde el alquilo de C₁₋₃ es opcionalmente sustituido por OH; R¹³ independientemente en cada caso es seleccionado de H, halo, CN, OH, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, ORᵃ³, SRᵃ³, C(=O)Rᵇ³, C(=O)NRᶜ³Rᵈ³, C(=O)ORᵃ³, OC(=O)Rᵇ³, OC(=O)NRᶜ³Rᵈ³, NRᶜ³Rᵈ³, NRᶜ³C(=O)Rᵇ³, NRᶜ³C(=O)NRᶜ³Rᵈ³, NRᶜ³C(=O)ORᵃ³, S(=O)Rᵇ³, S(=O)NRᶜ³Rᵈ³, S(=O)₂Rᵇ³, NRᶜ³S(=O)₂Rᵇ³ y S(=O)₂NRᶜ³Rᵈ³, en donde el alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ de R¹³ es opcionalmente sustituido con 1, 2, ó 3 grupos seleccionados independientemente de halo, CH, OH, ORᵃ³, SRᵃ³, C(=O)Rᵇ³, C(=O)NRᶜ³Rᵈ³, C(=O)ORᵃ³, OC(=O)Rᵇ³, OC(=O)NRᶜ³Rᵈ³, NRᶜ³Rᵈ³, NRᶜ³C(=O)Rᵇ³, NRᶜ³C(=O)NRᶜ³Rᵈ³, NRᶜ³C(=O)ORᵃ³, S(=O)Rᵇ³, S(=O)NRᶜ³Rᵈ³, S(=O)₂Rᵇ³, NRᶜ³S(=O)₂Rᵇ³ y S(=O)₂NRᶜ³Rᵈ³; R¹⁵ independientemente en cada caso es seleccionado de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, halo, CN, ORᵃ⁵, SRᵃ⁵, C(=O)Rᵇ⁵, C(=O)NRᶜ⁵Rᵈ⁵, C(=O)ORᵃ⁵, OC(=O)Rᵇ⁵, OC(=O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=O)Rᵇ⁵, NRᶜ⁵C(=O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=O)ORᵃ⁵, S(=O)Rᵇ⁵, S(=O)NRᶜ⁵Rᵈ⁵, S(=O)₂Rᵇ⁵, NRᶜ⁵S(=O)₂Rᵇ⁵, y S(=O)₂NRᶜ⁵Rᵈ⁵, en donde el alquilo C₁₋₆, cicloalquilo de C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, y heteroarilo de 5 - 6 miembros son cada uno opcionalmente sustituidos por 1, 2, ó 3 sustituyentes seleccionados independientemente de halo, CN, ORᵃ⁵, SRᵃ⁵, C(=O)Rᵇ⁵,
ARP140101029A 2013-03-15 2014-03-14 Heterociclos tricíclicos como inhibidores de la proteína bet AR095326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794812P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095326A1 true AR095326A1 (es) 2015-10-07

Family

ID=50639971

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101029A AR095326A1 (es) 2013-03-15 2014-03-14 Heterociclos tricíclicos como inhibidores de la proteína bet

Country Status (24)

Country Link
US (6) US9227985B2 (es)
EP (2) EP3581576B1 (es)
JP (3) JP6243003B2 (es)
KR (2) KR102355670B1 (es)
CN (2) CN109593096B (es)
AR (1) AR095326A1 (es)
AU (1) AU2014228175B2 (es)
BR (1) BR112015022942B1 (es)
CA (1) CA2903881C (es)
CL (1) CL2015002734A1 (es)
CR (1) CR20150513A (es)
EA (2) EA038494B1 (es)
EC (1) ECSP15043772A (es)
ES (2) ES2755827T3 (es)
IL (2) IL241158B (es)
MX (2) MX390039B (es)
NZ (1) NZ712453A (es)
PE (1) PE20151990A1 (es)
PH (2) PH12015502157A1 (es)
SG (2) SG10201707487VA (es)
TW (2) TWI719464B (es)
UA (1) UA119848C2 (es)
WO (1) WO2014143768A1 (es)
ZA (2) ZA201507255B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TWI719464B (zh) * 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP2016523964A (ja) * 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR20240134245A (ko) 2014-04-23 2024-09-06 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CN105985282B (zh) * 2015-01-28 2020-12-08 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN112409378A (zh) * 2015-09-08 2021-02-26 豪夫迈·罗氏有限公司 三环pi3k抑制剂化合物及其使用方法
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US20170121347A1 (en) * 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
EP3412669A4 (en) * 2016-02-05 2019-09-04 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
US10517877B2 (en) 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
EP4234554A3 (en) 2016-06-20 2023-12-27 Incyte Corporation Crystalline solid forms of a bet inhibitor
US11759533B2 (en) 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
CN110879294A (zh) * 2018-09-05 2020-03-13 成都市第三人民医院 蛋白标志物在诊断肠易激综合征的产品中的用途和用于诊断肠易激综合征的试剂盒
EP3873896A4 (en) * 2018-12-14 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
US20210265016A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Data Compression for Artificial Intelligence-Based Base Calling
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4289848A4 (en) * 2021-02-03 2024-08-07 Tuojie Biotech (Shanghai) Co., Ltd. FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, ITS PREPARATION PROCESS AND ITS PHARMACEUTICAL USE
CN117794546A (zh) * 2021-08-10 2024-03-29 葛兰素史密斯克莱有限责任公司 莫洛替尼组合疗法
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59170313A (ja) 1983-03-14 1984-09-26 Kurimoto Iron Works Ltd スクリ−ンゲ−ト
JPS6085739U (ja) 1983-11-18 1985-06-13 クラリオン株式会社 テ−プレコ−ダにおけるピンチロ−ラ装置
JPH0314566A (ja) * 1989-06-09 1991-01-23 Sankyo Co Ltd ベンズイミダゾール誘導体
US5244912A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
GB9410469D0 (en) * 1994-05-25 1994-07-13 Erba Farmitalia Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
FR2731708B1 (fr) * 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
FR2747678B1 (fr) 1996-04-22 1998-05-22 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
DE60115872T2 (de) 2000-04-21 2006-07-13 Pharmacia & Upjohn Co. Llc, Kalamazoo Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
CN1446218A (zh) * 2000-08-08 2003-10-01 圣诺菲-合成实验室公司 苯并咪唑衍生物,它们的制备方法以及它们的治疗应用
FR2816619B1 (fr) 2000-11-15 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
MXPA05005425A (es) * 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
WO2005080334A1 (ja) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102005011058A1 (de) * 2005-03-10 2006-09-14 Merck Patent Gmbh Substituierte Tetrahydro-pyrrolo-chinolinderivate
US20080318999A1 (en) * 2005-08-05 2008-12-25 Methvin Isaac Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
EP2147310A4 (en) 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009020559A2 (en) 2007-08-03 2009-02-12 The J. David Gladstone Institutes Agents that inhibit p-tefb interactions and methods of use thereof
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
DE102008052618A1 (de) 2008-10-21 2010-04-22 Henkel Ag & Co. Kgaa Tricyclische Aldehyde und C,H-acide Verbindungen
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
TW201105681A (en) * 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
WO2011054851A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
WO2011133722A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
AU2012220620A1 (en) 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2723338A2 (en) 2011-06-24 2014-04-30 The Trustees of Stevens Institute of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｈｉｖの治療のための組成物および方法
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
AU2012303954B2 (en) * 2011-08-31 2017-06-22 Otsuka Pharmaceutical Co., Ltd. Quinolone compound
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
WO2013044511A1 (zh) 2011-09-30 2013-04-04 沈阳蓝桑医药生物技术研发有限公司 含有瑞利格内酯的药物组合物及其应用
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150133434A1 (en) 2012-03-28 2015-05-14 The J. David Gladstone Institutes Compositions and Methods for Reactivating Latent Immunodeficiency Virus
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
HK1206744A1 (en) 2012-04-20 2016-01-15 Abbvie Inc. Isoindolone derivatives
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
MX2014015156A (es) 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
EP2863923B1 (en) 2012-06-25 2019-05-08 Oncoethix GmbH Thienotriazolodiazepine compounds for the treatment of lymphomas
US9610332B2 (en) 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
ES2653990T3 (es) 2012-08-16 2018-02-09 Glaxosmithkline Llc Benzodiazepinas para tratamiento del cáncer de pulmón de células pequeñas
PE20150729A1 (es) 2012-08-16 2015-06-14 Bayer Pharma AG 2,3-benzodiazepines
MX2015003771A (es) 2012-09-28 2016-03-04 Oncoethix Gmbh Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina.
WO2014048945A1 (de) 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
SI2917181T1 (sl) 2012-11-09 2020-01-31 Mmv Medicines For Malaria Venture Heteroarilni derivati in uporabe le-teh
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
EP2920183B1 (en) 2012-11-14 2017-03-08 Glaxosmithkline LLC Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
JP2016504990A (ja) 2012-12-20 2016-02-18 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン
WO2014095775A1 (de) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
BR112015022674A2 (pt) 2013-03-11 2017-07-18 Abbvie Inc inibidores de bromodomínio
CA2904048A1 (en) 2013-03-11 2014-10-09 Abbvie Inc. Bromodomain inhibitors
KR20150126696A (ko) 2013-03-12 2015-11-12 애브비 인코포레이티드 디하이드로-피롤로피리디논 브로모도메인 억제제
US9493411B2 (en) 2013-03-12 2016-11-15 Abbvie Inc. Pyrrole-3-carboxamide bromodomain inhibitors
JP6419735B2 (ja) 2013-03-12 2018-11-07 アッヴィ・インコーポレイテッド 四環系ブロモドメイン阻害剤
WO2014140077A1 (en) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
BR112015022417A2 (pt) 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
ES2704048T3 (es) 2013-03-14 2019-03-14 Glaxosmithkline Ip No 2 Ltd Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
US20160039842A1 (en) 2013-03-15 2016-02-11 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
US9199988B2 (en) 2013-03-27 2015-12-01 Boehringer Ingelheim International Gmbh Dihydroquinazolinone analogues
JP6370368B2 (ja) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害剤としてのインドリノン類似体
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
WO2014173241A1 (en) 2013-04-26 2014-10-30 Beigene, Ltd. Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
BR112015029353A2 (pt) 2013-05-28 2017-07-25 Novartis Ag derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
KR20160012195A (ko) 2013-05-28 2016-02-02 노파르티스 아게 Bet 억제제로서의 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
CA2915419A1 (en) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted phenyl-2,3-benzodiazepines
ITMI20130991A1 (it) 2013-06-17 2014-12-18 Industrie De Nora Spa Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse.
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SG11201510678TA (en) 2013-06-28 2016-01-28 Abbvie Inc Bromodomain inhibitors
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
PL3022191T3 (pl) 2013-07-16 2017-08-31 Basf Se Chwastobójcze azyny
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
KR101672096B1 (ko) 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
PE20161065A1 (es) 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
JP2016539970A (ja) 2013-12-09 2016-12-22 アッヴィ・インコーポレイテッド ブロモドメイン阻害薬として有用なジヒドロピリジノンおよびジヒドロピリダジノン誘導体
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
BR112016015311B1 (pt) 2014-01-09 2023-01-24 Orion Corporation Compostos derivados heterocíclicos bicíclicos, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar uma doença associada com bromodomínio
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
PL3134386T3 (pl) 2014-04-23 2020-11-16 Takeda Pharmaceutical Company Limited Pochodne izoindolin-1-onu jako dodatnia aktywność allosterycznego modulatora cholinergicznego receptora muskarynowego m1 do leczenia choroby alzheimera
AU2015250900B9 (en) 2014-04-23 2019-03-21 Basf Se Diaminotriazine compounds as herbicides
KR20240134245A (ko) 2014-04-23 2024-09-06 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
KR20160145833A (ko) 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
WO2015168555A1 (en) 2014-05-02 2015-11-05 Oncoethix Sa Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
WO2015169953A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating glioma using thienotriazolodiazepine compounds
BR112016026046A8 (pt) 2014-05-08 2021-07-20 Oncoethix Gmbh uso de compostos de tienotriazolodiazepina
EP3148543B1 (en) 2014-05-30 2020-04-08 Icahn School of Medicine at Mount Sinai Small molecule transcription modulators of bromodomains
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
HUE050706T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CA2974153A1 (en) 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
CA2987384A1 (en) 2015-05-29 2016-12-08 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
CN105039258B (zh) 2015-07-03 2018-04-17 北京大学 将非神经元细胞重编程为神经元样细胞的方法和组合物
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105254635A (zh) 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
US20170127985A1 (en) 2015-11-11 2017-05-11 Medtronic Minimed, Inc. Sensor set
CA3007168A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
EP3412669A4 (en) 2016-02-05 2019-09-04 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4234554A3 (en) 2016-06-20 2023-12-27 Incyte Corporation Crystalline solid forms of a bet inhibitor
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用

Also Published As

Publication number Publication date
US10919912B2 (en) 2021-02-16
AU2014228175A1 (en) 2015-10-08
JP2016513716A (ja) 2016-05-16
UA119848C2 (uk) 2019-08-27
US11498926B2 (en) 2022-11-15
ES2755827T3 (es) 2020-04-23
US9624241B2 (en) 2017-04-18
MX366703B (es) 2019-07-22
TW201512198A (zh) 2015-04-01
JP2018008958A (ja) 2018-01-18
EP3581576B1 (en) 2022-01-26
BR112015022942B1 (pt) 2022-02-22
TWI719464B (zh) 2021-02-21
CN105164131B (zh) 2018-12-28
US9227985B2 (en) 2016-01-05
US20210188872A1 (en) 2021-06-24
US10464947B2 (en) 2019-11-05
PH12015502157A1 (en) 2016-01-25
EA035469B1 (ru) 2020-06-22
CN105164131A (zh) 2015-12-16
IL241158B (en) 2019-07-31
NZ712453A (en) 2020-06-26
US9938294B2 (en) 2018-04-10
MX390039B (es) 2025-03-20
CN109593096A (zh) 2019-04-09
CR20150513A (es) 2016-01-04
MX2015013149A (es) 2016-01-08
CA2903881A1 (en) 2014-09-18
WO2014143768A1 (en) 2014-09-18
US20170210754A1 (en) 2017-07-27
US20180346481A1 (en) 2018-12-06
PE20151990A1 (es) 2016-01-13
JP6529546B2 (ja) 2019-06-12
SG10201707487VA (en) 2017-10-30
KR20150136497A (ko) 2015-12-07
US20140275030A1 (en) 2014-09-18
BR112015022942A2 (pt) 2017-07-18
TW201930303A (zh) 2019-08-01
JP2019142973A (ja) 2019-08-29
TWI667238B (zh) 2019-08-01
EP2970282B1 (en) 2019-08-21
IL267609B (en) 2020-07-30
JP6243003B2 (ja) 2017-12-06
HK1218650A1 (en) 2017-03-03
ES2909778T3 (es) 2022-05-10
EA038494B1 (ru) 2021-09-07
CA2903881C (en) 2021-05-18
JP6712344B2 (ja) 2020-06-17
ECSP15043772A (es) 2017-08-31
CL2015002734A1 (es) 2016-03-28
IL267609A (en) 2019-08-29
PH12019502318A1 (en) 2020-12-07
EP2970282A1 (en) 2016-01-20
KR102355670B1 (ko) 2022-02-08
US20200131195A1 (en) 2020-04-30
IL241158A0 (en) 2015-11-30
EA201591785A1 (ru) 2015-12-30
US20160046650A1 (en) 2016-02-18
ZA201507255B (en) 2023-03-29
KR102216288B1 (ko) 2021-02-18
MX2019008521A (es) 2019-10-30
CN109593096B (zh) 2022-01-14
KR20210021090A (ko) 2021-02-24
AU2014228175B2 (en) 2018-05-31
EP3581576A1 (en) 2019-12-18
ZA202001242B (en) 2021-08-25
EA201992712A3 (ru) 2020-05-31
SG11201506924YA (en) 2015-09-29
EA201992712A2 (ru) 2020-03-31

Similar Documents

Publication Publication Date Title
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR092742A1 (es) Piridinonas antifibroticas
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR096241A1 (es) Inhibidores de acc y usos de los mismos
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR096242A1 (es) Inhibidores de acc y usos de los mismos
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR088801A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR088327A1 (es) Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes
AR108207A1 (es) Derivados de pirrolo[2,3-c]piridina, inhibidores de bromodominios
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
BR112015018509A2 (pt) compostos de imidazo piridina
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas

Legal Events

Date Code Title Description
FG Grant, registration